These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18183660)

  • 1. American Society of Hematology annual meeting.
    Fricker J
    Lancet Oncol; 2008 Jan; 9(1):13. PubMed ID: 18183660
    [No Abstract]   [Full Text] [Related]  

  • 2. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

  • 3. Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib.
    Gentile M; Guido M; Lucia E; Vigna E; Mazzone C; Recchia AG; Morabito F
    Leuk Lymphoma; 2014 Mar; 55(3):709-10. PubMed ID: 23741978
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment-free remission after stopping second-line dasatinib.
    Ross DM
    Lancet Haematol; 2015 Dec; 2(12):e506-7. PubMed ID: 26686401
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.
    Valent P
    Haematologica; 2011 Oct; 96(10):1395-7. PubMed ID: 21972208
    [No Abstract]   [Full Text] [Related]  

  • 6. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
    [No Abstract]   [Full Text] [Related]  

  • 7. New drugs: paliperidone, dasatinib, and decitabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013
    [No Abstract]   [Full Text] [Related]  

  • 8. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
    Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
    Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
    [No Abstract]   [Full Text] [Related]  

  • 11. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
    J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
    Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K
    Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib is effective in imatinib-resistant CML.
    Cannell E
    Lancet Oncol; 2007 Apr; 8(4):286. PubMed ID: 17431950
    [No Abstract]   [Full Text] [Related]  

  • 17. Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
    Tecchio C; Nichele I; Todeschini G; Pizzolo G; Ambrosetti A
    Br J Haematol; 2009 Jul; 146(2):222-3. PubMed ID: 19466973
    [No Abstract]   [Full Text] [Related]  

  • 18. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
    Wang HC; Lee CS; Liu TC
    Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
    [No Abstract]   [Full Text] [Related]  

  • 19. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
    Ali S; Sergeant R; O'Brien SG; Foroni L; Hedgley C; Gerrard G; Milojkovic D; Stringaris K; Khoder A; Alsuliman A; Gilleece M; Gabriel IH; Cooper N; Goldman JM; Apperley JF; Clark RE; Marin D; Rezvani K
    Blood; 2012 Jul; 120(3):697-8. PubMed ID: 22822001
    [No Abstract]   [Full Text] [Related]  

  • 20. Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
    Wolf D
    Eur J Haematol; 2015 Mar; 94(3):189-90. PubMed ID: 25712068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.